相关实验视频

Updated: Jan 11, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

LINC02178驱动肺腺癌的进展,并作为基于纳米输送的干预的治疗目标

Lizhong Zeng¹, Haimei Wen¹, Tong Jiao¹

¹Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Scientific reports

|November 10, 2025

概括

研究人员确定LINC02178是肺腺癌 (LUAD) 的致癌驱动因素. 一个以纳米粒子为基础的传递系统针对这种长非编码RNA (lncRNA) 显示了在LUAD治疗中基因治疗的前景.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
纳米技术纳米技术

背景情况:

肺腺癌 (LUAD) 是癌症死亡的主要原因.
基因疗法为癌症治疗提供了一个有前途的途径.
长非编码RNAs (lncRNAs) 越来越多地被认为是癌症中的角色.

研究的目的:

为了确定LUAD中的瘤驱动因素.
开发一种基于纳米粒子的新型基因传递系统,用于针对特定的lncRNAs.
评估该系统在LUAD中的治疗潜力和生物安全性.

主要方法:

生物信息学分析以确定LINC02178作为候选瘤基因.
基于纳米粒子的小干扰RNA输送系统的开发 (NPs/2178).
在体外测试 (细胞活力,细胞亡,增殖) 和体内异种移植小鼠模型,以评估疗效和毒性.

主要成果:

在LUAD组织中,LINC02178表达升高,与预后不佳相关.
NPs/2178系统有效地传递了小干扰RNA,导致LINC02178的敲击.
NPs/2178在体内表现出显著的LUAD细胞亡诱导,增殖抑制和瘤生长抑制,毒性最小.

结论:

LINC02178 作为促进LUAD进展的致癌因素.
基于纳米粒子的LINC02178传递系统是LUAD的可行和有前途的基因治疗策略.
这个平台为开发针对LUAD的向基因疗法提供了新的见解.

关键词:

细胞灭亡 (apoptosis) 是一种死亡的过程.基因治疗是一种基因疗法.现在我们来看看LINC0217878的情况.肺部腺癌瘤是肺部腺癌.核武器的扩散

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...